Research Firm Sees mHealth as Top Global Healthcare Trend

Dec. 10, 2013
Research firm Frost & Sullivan has listed mHealth as the top area of growth for the global healthcare market in 2014 as beyond, as indicated by a survey involving 1,835 executives in more than 40 countries worldwide.

Research firm Frost & Sullivan has listed mHealth as the top area of growth for the global healthcare market in 2014 as beyond, as indicated by a survey involving 1,835 executives in more than 40 countries worldwide.

According to the '2013 Search for Growth' survey, mHealth, cloud computing, and regulatory environments will be the key subjects in 2014 and beyond. mHealth expansion has been fuelled by the unprecedented spread of mobile technologies, as well as advancements in their innovative application to address health priorities. It is largely supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants (PDAs), and other wireless devices. The penetration prospects of mHealth technologies are significant in the following areas: wireless vital signs monitoring, location-aware telemonitoring systems, and Bluetooth wireless technology-enabled health trackers, the company said in a press release.

Additionally, as more healthcare IT and patient monitoring tools are integrated, every hospital facility will eventually have to acquire a fully-enterprise wireless solution. The most innovative mobile healthcare solutions that best meet pressing healthcare needs will be adopted as the gold standard, said Frost & Sullivan.

Enterprise-wide healthcare informatics will also improve the quality of medical services and efficiency of operations while reducing expenditures. Cloud computing is considered to be a key enabler for enterprise-wide solutions. Implementing cloud computing technologies appropriately will help healthcare providers improve the quality of medical services and the efficiency of operations, share information across geographic locations, and manage expenditures. The concept can be applied in a variety of ways, including data storage and data loss prevention, maintaining patient information records, and authorized sharing of information, according to the company's research. 

As for regulatory environment, researchers said that recent healthcare reforms and policy initiatives across many countries have emphasized the importance of quality of care more than quantity. In the absence of a sufficient proof of clinical benefit, reimbursements may pose a major hurdle.

All in all, three big predictions may be formulated based on the survey's results:

  • As healthcare is geared towards a personalized medicine model, companion diagnostics will alter drug development and the commercialization process of drug candidates. Combining biomarkers and drugs will result in enhanced therapeutic efficacy and safety.
  • The healthcare and life sciences industry will consolidate further in this decade, with many big pharma companies seeking alternatives to the blockbuster model.
  • The rise of new technologies capable of integrating medical devices into a connected platform will enhance the functionality of devices, reduce the manpower burden and minimize errors.

Sponsored Recommendations

Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

Beyond the Silos: Transforming Coordinated Care Across Healthcare Systems

Coordinated healthcare is vital to delivering a high-quality patient experience, yet it has been difficult to systematize across all healthcare settings. Although it has largely...

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1